SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2013 / Cilt: 23 - Sayı: 1

Hematopoietik kök hücre transplantasyonu (hkht)’nda tıbbi beslenme tedavisi

Medical nutritional therapy in hematopoietic stem cell transplantation (hsct)

GAMZE AKBULUT
Pages
55–65
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is important that dietary guidancefor HSCT patients to minimize the risk of microbial exposure, optimize nutrient consumption and energy intake is very important

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hematopoietic Stem Cell Transplantation (HSCT) is a method used for the treatment of patients with severe aplastic anemia, leukaemia and some other malignancies.
📊
Key Findings & Data:As it causes many adverse sequelaes (anorexia, nausea, vomiting, diarrhea, and mucositis), adequate oral diet is usually unachievable and artificial nutrition support is required.
💡
Conclusion & Impact:It is important that dietary guidancefor HSCT patients to minimize the risk of microbial exposure, optimize nutrient consumption and energy intake is very important
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hematopoietic Stem Cell Transplantation (HSCT) is a method used for the treatment of patients with severe aplastic anemia, leukaemia and some other malignancies. As it causes many adverse sequelaes (anorexia, nausea, vomiting, diarrhea, and mucositis), adequate oral diet is usually unachievable and artificial nutrition support is required. In order to reduce the risk of infections, the protective benefit of “low-microbial / neutropenic diets” is suggested to use in immunosuppressed patients. Traditionally, total parenteral nutrition (TPN) has been the chosen method for the nutritional support of patients undergoing HSCT. Secondly enteral nu trition (especially with enteral tube feeding - ETF) is an alternative method for nutritional support. It is important that dietary guidancefor HSCT patients to minimize the risk of microbial exposure, optimize nutrient consumption and energy intake is very important

Özet

Hematopoietik Kök Hücre Transplantasyonu (HKHT) ağır aplastik anemi, lösemi ve diğer bazı maligniteleri olan hastaların tedavisi için kullanılan bir yöntemdir. Hastalık birçok yan etkilere (iştahsızlık, bulantı, kusma, ishal ve mukozit) neden olduğundan, çoğunlukla yeterli oral beslenme sağlanamamakta ve beslenme desteği gerekmektedir. Bağışıklığı baskılanmış hastalarda enfeksiyonların riskini azaltmak için "düşük-mikrobiyal / nötropenik diyetler" koruyucu yarar sağlaması nedeniyle önerilmektedir. Geleneksel olarak, HKHT uygulanan hastalarda total parenteral beslenme (TPN), beslenme desteği için seçilen yöntem olmuştur. İkinci bir yöntem olan enteral beslenme uygulaması (özellikle enteral tüp ile beslenme - ETB), beslenme desteği için alternatif bir yöntemdir. HKHT hastalarına yönelik oluşturulan diyet rehberlerinde, enfeksiyona maruz kalma riskini en aza indirgemek amacıyla optimal besin tüketimi ve enerji alımıçok önemlidir.

🔖

Cite This Article

AKBULUT, G. (2013). Hematopoietik kök hücre transplantasyonu (hkht)’nda tıbbi beslenme tedavisi. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 23 - Sayı: 1, 55–65. https://ajindex.com/articles/322899

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant 37: 439-449, 2006
  2. Muscaritoli M, Grieco G, Capria S, et al. Nutritional and metabolic support in patients undergoing bone mar- row transplantation. Am J Clin Nutr 75:183-190, 2002
  3. Ordóñez FJ, Jiménez FJ, Delgado JA. Parenteral nutri- tion in hematologic patients treated with hematopoiet- ic stem cell transplantation. Nutr Hosp 15: 114-120, 2000. 4.Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4: 224-232, 2003
  4. Lenssen P. Hematopoietic Stem Cell Transplantation. In: Contemporary Nutrition Support Practice. Matarese LE, Gottschlich MM (eds). 2nd ed. Missouri, Saunders, 2003: 574-594
  5. Majhail NS, Flowers ME, Ness KK, et al. High preva- lence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 43: 49-54, 2009
  6. Le Blanc K, Ringden O, Remberger M. A low body mass index is correlated with poor survival after allo- geneic stem cell transplantation. Haematologica 88:1044-1052, 2003
  7. Borelli P, Barros FE, Nakajima K, et al. Protein-energy malnutrition halts hemopoietic progenitor cells in the G0/G1 cell cycle stage, thereby altering cell production rates. Braz J Med Biol Res 42: 523-530, 2009
  8. Argilés M, Busquets S, López Soriano FJ, et al. Pathophysiology of neoplasic cachexia. Nutr Hosp 21: 214-219, 2006
  9. Rzepecki P, Barzal J, Oborska S. Blood and marrow transplantation and nutritional support. Support Care Cancer 18 (Suppl 2): 57-65, 2010
  10. Aker SN. Bone marrow transplantation: nutrition sup- port and monitoring. In: Nutrition management of the cancer patient. Bloch AS(ed): Rockville, Aspen Pub- lishing, 1990: 199-225
  11. Deeg HJ, Seidel K, Bruemmer B, et al. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 15: 461- 468, 1995
  12. Deeg HJ, Seidel K, Sullivan KM. Body weight and out- come of hematopoietic stem cell transplantation. Am J Med 104: 607-608, 1998
  13. Goldberg SL, Klumpp TR, Magdalinski AJ, et al. Value of the pretransplant evaluation in predicting toxic day- 100 mortality among blood stem-cell and bone mar- row transplant recipients. J Clin Oncol 16: 3796-3802, 199